MIMPARA 60 MG
Country: Iżrael
Lingwa: Ingliż
Sors: Ministry of Health
Xi dokumenti għal dan il-prodott mhumiex disponibbli bħalissa, tista 'tibgħat talba lis-servizz tal-konsumatur tagħna u aħna ninnotifikawkom malli nkunu nistgħu niksbuhom.
Ibgħat talba.
Ibgħat talba.
Ingredjent attiv:
CINACALCET HYDROCHLORIDE 60 MG
Disponibbli minn:
AMGEN EUROPE B.V.
Kodiċi ATC:
H05BX01
Għamla farmaċewtika:
FILM COATED TABLETS
Rotta amministrattiva:
PER OS
Manifatturat minn:
AMGEN EUROPE B.V., NETHERLANDS
Grupp terapewtiku:
CINACALCET
Indikazzjonijiet terapewtiċi:
Treatment of secondary hyperparathyrodism (HPT) in patients with end-dtage renal disease (ESRD) on maintenance dialysis therapy. Mimpara may be used as part of a therapeutic regimen including phosphate binders and/or Vitamin D sterols, as appropriate. Reduction of hypercalcaemia in patients with parathyroid carcinoma.
Data ta 'l-awtorizzazzjoni:
2012-10-01
